Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility trial of cisplatin doublets plus hypofractionated radiotherapy in locally advanced or inoperable non-small cell lung carcinoma
2016-003790-18Phase 2Active
- Sponsor
- Netherlands Cancer Institute
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin in non-small cell lung cancer (NSCLC), sponsored by Netherlands Cancer Institute. Primary endpoint: Incidence of grade 3-5 toxicity. Started Nov 2016; status: active.
02
Drugs
cisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2016-003790-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003790-18.